Clinical trials: Stage IV, NSCLC
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
This clinical trial compares the use of a shared decision-making communication tool during a clinical encounter to standard care for improving the quality of the shared decision-making process among patients with non-small cell…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06122064
- Testing
- Best Practice, Communication Intervention, Electronic Health Record Review
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth…
- Conditions
- Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT05110118
- Testing
- LY01008, Avastin
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Lung Cancer
ERCC1 Targeted Trial
Lung cancer is the leading cause of cancer death in the UK, leading to 34 000 deaths each year (22% of cancer deaths). Non-small cell lung cancer (NSCLC) is the most common histology, accounting for approximately 80% of cases and…
- Trial name
- ET (NCT00801736)
- Testing
- Cisplatin, Paclitaxel
- Where
- United Kingdom
- Volunteers
- 648 people, healthy volunteers welcome
- Sponsor
- University College, London
Non-Small-Cell Lung Carcinoma
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70…
- Trial name
- NCT00137800
- Testing
- OSI-774 (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
This randomized pilot clinical trial studies exercise intervention in improving quality of life and exercise capacity and reducing inflammation and oxidative stress in patients with lung cancer and their support persons.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01999881
- Testing
- exercise intervention, standard follow-up care, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Lung Cancer
Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…
- Trial name
- NCT00899028
- Testing
- comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis
- Where
- 4 sites in United States
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
NSCLC Stage IV
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
Pembrolizumab is approved for advanced stage non-small cell lung cancer. However, the response rate is low (around 10-15 %) in patients treated in Macau SAR, China.
- Trial name
- NCT04076228
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Kiang Wu Hospital